About Pardes Biosciences
Pardes Biosciences is a company based in Berkeley (United States) founded in 2020 was acquired by Foresite Capital in July 2023.. Pardes Biosciences has raised $51.61 million across 1 funding round from investors including Foresite Capital. The company has 29 employees as of December 31, 2021. Pardes Biosciences operates in a competitive market with competitors including ExeVir Bio, Vaxxinity, NRx, Inimmune and IMUNON, among others.
- Headquarter Berkeley, United States
- Employees 29 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Pardes Biosciences, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$51.61 M (USD)
in 1 rounds
-
Latest Funding Round
$51.61 M (USD), Series C
Feb 03, 2021
- Investors
-
Employee Count
29
as on Dec 31, 2021
-
Acquired by
Foresite Capital
(Jul 17, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Funding Insights of Pardes Biosciences
Pardes Biosciences has successfully raised a total of $51.61M through 1 strategic funding round. The most recent funding activity was a Series C round of $51.61 million completed in February 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series C — $51.6M
-
First Round
First Round
(03 Feb 2021)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2021 | Amount | Series C - Pardes Biosciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Pardes Biosciences
Pardes Biosciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Foresite Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Pardes Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Pardes Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Pardes Biosciences Comparisons
Competitors of Pardes Biosciences
Pardes Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ExeVir Bio, Vaxxinity, NRx, Inimmune and IMUNON, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Provider of antibody-based therapies to monitor viral infections
|
|
| domain | founded_year | HQ Location |
Vaccines for neurological disorders and infectious diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for COVID-19 and neurological disorders are developed.
|
|
| domain | founded_year | HQ Location |
Integrated clinical developmental services to treat food allergy, allergic rhinitis, and auto-immune disorders
|
|
| domain | founded_year | HQ Location |
Immunotherapeutics for cancer treatment are developed using DNA-based platforms.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Pardes Biosciences
Frequently Asked Questions about Pardes Biosciences
When was Pardes Biosciences founded?
Pardes Biosciences was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Where is Pardes Biosciences located?
Pardes Biosciences is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Is Pardes Biosciences a funded company?
Pardes Biosciences is a funded company, having raised a total of $51.61M across 1 funding round to date. The company's 1st funding round was a Series C of $51.61M, raised on Feb 03, 2021.
How many employees does Pardes Biosciences have?
As of Dec 31, 2021, the latest employee count at Pardes Biosciences is 29.
What does Pardes Biosciences do?
Pardes Biosciences was founded in 2020 and is based in Berkeley, United States. Focus is placed on the biotechnology sector, where therapeutics for pandemic diseases are developed. Operations center on antiviral drug candidates, with the lead product PBI-0451 serving as an oral coronaviral protease inhibitor. This compound is targeted at treating and preventing SARS-CoV-2 infections in clinical settings.
Who are the top competitors of Pardes Biosciences?
Pardes Biosciences's top competitors include NRx, ExeVir Bio and Ashvattha Therapeutics.
Who are Pardes Biosciences's investors?
Pardes Biosciences has 1 investor. Key investors include Foresite Capital.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.